Last week, I attended Oracle OpenWorld in San Francisco which is the single largest gathering of Oracle technology experts. The session I participated in, was called “Transformational Steps Toward Modernizing Life Sciences R&D”. In the session, we looked at how the cloud has the power to give pharmaceutical companies better insights into their R&D data by enabling efficient and consistent access to multiple sources of information. These insights empower better decision making, reduced drug R&D times, and ultimately, improved patient outcomes. Pharma companies may even realize some cost benefits through these efficiencies.
We also conducted a demo of the Accenture-Oracle Life Sciences solution Accenture Life Sciences Cloud for R&D to show the potential this platform has to improve patient outcomes and efficiencies in drug R&D cycles.
The conversations at Oracle OpenWorld align to what Sunil suggests – adoption of cloud solutions has been slow in life sciences but interest is building because they see the potential for clinical development and other operations.
If you weren’t able to attend, check out some of the Accenture photos at Oracle OpenWorld 2013.